The Journey of Rituximab

Rituximab is a large chimeric IgG1 antibody (~144 kDa) that
must be administered intravenously — oral or subcutaneous administration of the standard formulation
is not used due to the molecular size and proteolytic degradation considerations. Intravenous
infusion provides 100% bioavailability with immediate peak concentrations. A subcutaneous formulation
co-formulated with recombinant human hyaluronidase (MabThera SC/Rituxan Hycela) was developed for
NHL and CLL, achieving bioavailability of approximately 78% via a fast 5-minute injection rather
than the 90-minute to 4-hour IV infusions. IV infusion rates must be carefully titrated: infusion-
related reactions (fever, chills, rigors, hypotension — primarily cytokine release from CD20+
B cell death and mast cell degranulation triggered by complement activation) are most severe
during the first infusion and diminish substantially with subsequent infusions as B cells are
progressively depleted.

As an IgG1 monoclonal antibody, rituximab distributes with
a volume of distribution of approximately 3.1-4.6 L — confined largely to plasma and interstitial
fluid. The IgG1 Fc region mediates FcRn-mediated recycling, protecting rituximab from lysosomal
catabolism and contributing to its extended half-life. Rituximab distributes to lymphoid tissues
(lymph nodes, spleen, bone marrow) via the lymphatic system and enhanced vascular permeability,
reaching B cell-rich compartments at therapeutically meaningful concentrations. CNS penetration
is minimal under normal conditions (the blood-brain barrier prevents large antibody entry), which
limits rituximab's efficacy in CNS lymphoma as monotherapy. Bone marrow B cells are accessible
via sinusoidal vasculature. After B cell depletion, rituximab persists in circulation due to
reduced target-mediated clearance.

CD20 (MS4A1) is a non-glycosylated phosphoprotein and tetraspan
channel expressed exclusively on pre-B cells, mature B lymphocytes, and malignant B cells —
absent on plasma cells, hematopoietic stem cells, and dendritic cells. It plays a role in B cell
activation and calcium signaling but has no known natural ligand (making it an ideal therapeutic
target — depletion does not eliminate the crucial non-B cell immune compartments). Rituximab binds
the extracellular loop of CD20 with high affinity (Kd ~1-8 nM) and triggers B cell death through
three mechanisms: (1) Complement-dependent cytotoxicity (CDC): Fc region activates C1q, generating
membrane attack complex (MAC) on the B cell surface — dominant in lymph nodes with high complement
availability; (2) Antibody-dependent cellular cytotoxicity (ADCC): Fc-gamma RIII (CD16) on NK
cells and macrophages recognizes Fc-bound rituximab, triggering granule exocytosis and B cell
lysis — dominant in blood and spleen; (3) Direct apoptosis induction via caspase pathway
activation after CD20 crosslinking.

Rituximab, as a protein therapeutic, is catabolized by the
ubiquitous proteolytic machinery for IgG antibodies. No CYP450 enzymes are involved. Target-mediated
drug disposition (TMDD) is prominent: at low B cell counts (after depletion), rituximab clearance
is lower and half-life longer because CD20-mediated internalization is the primary elimination
mechanism (when B cells are abundant). Anti-chimeric human antibodies (HACA — human anti-chimeric
antibodies) develop in approximately 1-4% of patients and can reduce efficacy and cause infusion
reactions. The chimeric nature (mouse variable regions, human constant regions) was a step in
antibody humanization — fully humanized or human anti-CD20 antibodies (obinutuzumab, ofatumumab)
have lower immunogenicity and in some cases superior efficacy through enhanced ADCC.

Rituximab is eliminated by proteolytic catabolism throughout the
body; no intact antibody is excreted in urine or feces. The terminal half-life after the first
infusion is approximately 76 hours; after the fourth infusion (with progressive B cell depletion),
it increases to approximately 205 hours, reflecting reduced TMDD as CD20-expressing B cells become
depleted. Clearance ranges from approximately 0.33 L/day (1st infusion) to 0.14 L/day (4th infusion)
— declining as B cell burden falls. B cell recovery after rituximab begins at 6-9 months and normal
B cell counts are generally restored by 12 months — though in some patients, B cell counts remain
depressed for 2+ years. This prolonged immunosuppression necessitates infectious prophylaxis and
screening for hepatitis B reactivation before initiating treatment.

Rituximab transformed the treatment of B cell non-Hodgkin's lymphoma
and CLL — the addition of rituximab to CHOP chemotherapy (R-CHOP) reduced mortality by approximately
30% in diffuse large B cell lymphoma. It is also approved for rheumatoid arthritis (after TNF
inhibitor failure), granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and
pemphigus vulgaris. Serious adverse effects include infusion reactions, severe mucocutaneous reactions
(SJS/TEN, rare), progressive multifocal leukoencephalopathy (PML — JC virus reactivation, uncommon
but fatal), and prolonged immunosuppression with infection risk. Hepatitis B reactivation (potentially
fatal) requires HBsAg/HBcAb screening and antiviral prophylaxis for all patients. Rituximab is
not effective in plasma cell disorders (multiple myeloma) as plasma cells do not express CD20.